Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immutep Ltd.
PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.
Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Immutep S.A.S.
- Immutep GmbH
- Immutep, U.S., Inc.
- Prima BioMed Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.